Hualan Biological Vaccine, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Hualan Biological Vaccine, Inc.

Why is Hualan Biological Vaccine, Inc. ?

Poor long term growth as Net Sales has grown by an annual rate of -17.28% and Operating profit at -56.68% over the last 5 years

The company has declared Negative results for the last 4 consecutive quarters

NET SALES(HY) At CNY 191.05 MM has Grown at -73.49%
OPERATING CASH FLOW(Y) Lowest at CNY 460.54 MM
ROCE(HY) Lowest at 3.23%

With ROE of 3.08%, it has a very attractive valuation with a 0.39 Price to Book Value

Over the past year, while the stock has generated a return of 19.31%, its profits have fallen by -75.5%
At the current price, the company has a high dividend yield of 1.2

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Hualan Biological Vaccine, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Hualan Biological Vaccine, Inc. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Hualan Biological Vaccine, Inc.

4.6%

0.78

43.97%

China Shanghai Composite

14.61%

1.01

15.10%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

-17.28%

EBIT Growth (5y)

-56.68%

EBIT to Interest (avg)

70.38

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.31

Sales to Capital Employed (avg)

0.27

Tax Ratio

3.33%

Dividend Payout Ratio

58.21%

Pledged Shares

Institutional Holding

ROCE (avg)

16.43%

ROE (avg)

9.48%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

Industry P/E

Price to Book Value

0.39

EV to EBIT

-8.33

EV to EBITDA

-3.21

EV to Capital Employed

-0.26

EV to Sales

-0.65

PEG Ratio

Dividend Yield

1.17%

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

3.08%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

Mildly Bullish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company

RAW MATERIAL COST(Y)

Fallen by -541.47% (YoY

-23What is not working for the Company

NET SALES(HY)

At CNY 191.05 MM has Grown at -73.49%

OPERATING CASH FLOW(Y)

Lowest at CNY 460.54 MM

ROCE(HY)

Lowest at 3.23%

DEBTORS TURNOVER RATIO(HY)

Lowest at 0.78%

PRE-TAX PROFIT(Q)

At CNY 29.89 MM has Fallen at -37.16%

NET PROFIT(Q)

At CNY 27.72 MM has Fallen at -39.35%

Here's what is working for Hualan Biological Vaccine, Inc.

Raw Material Cost

Fallen by -541.47% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Hualan Biological Vaccine, Inc.

Net Sales

At CNY 191.05 MM has Grown at -73.49%

Year on Year (YoY)

MOJO Watch

Near term sales trend is very negative

Net Sales (CNY MM)

Operating Cash Flow

Lowest at CNY 460.54 MM

in the last three years

MOJO Watch

The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Pre-Tax Profit

At CNY 29.89 MM has Fallen at -37.16%

over average net sales of the previous four periods of CNY 47.56 MM

MOJO Watch

Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Net Profit

At CNY 27.72 MM has Fallen at -39.35%

over average net sales of the previous four periods of CNY 45.71 MM

MOJO Watch

Near term Net Profit trend is negative

Net Profit (CNY MM)

Debtors Turnover Ratio

Lowest at 0.78%

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio

Non Operating Income

Highest at CNY 0.64 MM

in the last five periods

MOJO Watch

Increased income from non business activities may not be sustainable

Non Operating income